Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Integrated Oncology - a LabCorp Specialty Testing Group; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Community Practice Connections™: 15th Annual New York Lung Cancers Symposium®

Release Date: January 29, 2021
Expiration Date: January 29, 2022

Activity Overview

Community Practice Connections™: 15th Annual New York Lung Cancers Symposium® consists of a series of short summaries of recent clinical data, interactive clinical vignettes, and short video interviews of leading experts in lung cancer. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Integrated Oncology - a LabCorp Specialty Testing Group; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, and pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other health care professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

•Assess testing strategies to optimize tumor characterization and inform clinical decision-making for the management of patients with lung cancers
•Evaluate emerging clinical evidence regarding the management of patients with nonmetastatic lung cancers
•Assess clinical data concerning single-agent and combination immunotherapeutic approaches to manage lung cancers
•Explain current and emerging therapeutic strategies over multiple lines of therapy for patients with oncogene-driven NSCLC subtypes
•Identify strategies for patients without actionable oncogenic drivers, including the role of chemotherapies and antiangiogenic strategies
•Describe approaches to mitigate and manage treatment-related toxicities in the care of patients with lung cancers

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Javier Pinilla-Ibarz, MD, PhD
Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosures: Consultant: AstraZeneca, Pfizer, Daiichi Sankyo


Catherine C. Coombs, MD
Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Director, Cancer Center
Albert Einstein College of Medicine
Bronx, NY

Disclosures: Grant Research Support: National Cancer Institute; Consultant: GlaxoSmithKline, AstraZeneca, Clovis Oncology, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero; Shareholder: Stelexis

Alexey Danilov, MD, PhD
Matthew D. Hellmann, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosures: Grant Research Support: Bristol Myers Squibb, Genentech; Consultant: Compensated consultant for Merck, Bristol Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; Shareholder: Has options from Shattuck Labs, Immunai, and Arcus; Other: Received travel support honoraria from AstraZeneca, Eli Lilly, and Bristol Myers Squibb.

Sameh Gaballa, MD
Tony S. Mok, MD, FRCPC, FASCO
Li Shu Fan Medical Foundation Endowed Professor
and Chairman
Department of Clinical Oncology
The Chinese University of Hong Kong
Sha Tin, Hong Kong
 

Disclosures: Grant Research Support: AstraZeneca, Bristol Myers Squibb, Clovis Oncology, G1 Therapeutics, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche, SFJ, Takeda, XCovery; Consultant: AbbVie, ACEA Therapeutics, Amgen AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cirina, CStone Pharmaceuticals, Daiichi Sankyo, Lilly, Fishawack Health, G1 Therapeutics, Gritstone Oncology, GeneDecode (uncompensated), Hengrui Therapeutics, Hutchison China MedTech, Ignyta, Incyte Corporation, IQVIA, Janssen, Loxo Oncology, Lunit, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, Novartis, OncoGenex Technologies, OrigiMed, Pfizer, Roche/Genentech, Sanofi-Aventis, R&D, SFJ Pharmaceuticals, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical, Yuhan Corporation; Shareholder: Sanomics, Hutchison China MediTech; Other: Board of Directors: AstraZeneca Hutchison China MediTech.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
282930
Filter By